DAGLβ-IN-1 is primarily utilized in research settings to study the role of diacylglycerol lipase beta (DAGLβ) in biological processes. It serves as a selective inhibitor of DAGLβ, an enzyme involved in the biosynthesis of 2-arachidonoylglycerol (2-AG), a key endocannabinoid. By inhibiting DAGLβ, researchers can explore the physiological and pathological functions of 2-AG in the endocannabinoid system, particularly in contexts such as inflammation, neuroinflammation, and neurodegenerative diseases. This compound is valuable for understanding the therapeutic potential of modulating endocannabinoid signaling pathways, which may lead to the development of treatments for conditions like chronic pain, multiple sclerosis, and other disorders linked to dysregulated endocannabinoid activity.